Age in years

Sex

Race/ethnicity

Geographical location

Duration of type 2 diabetes mellitus in years ·

Known cardiovascular disease—does the participant have history of atherosclerotic cardiovascular disease (coronary, cerebrovascular or peripheral vascular disease—see ICD10 codes below*) (y/n) ·

Use of any concomitant glucose lowering agents at baseline (y/n)

Use of metformin at baseline (y/n)

Use of sulphonylurea at baseline (y/n)

Use of thiazolidinediones at baseline (y/n)

Use of DPP4 inhibitor at baseline (y/n) ·

Use of GLP1 receptor agonist at baseline (y/n)

Use of SGLT2 inhibitor at baseline (y/n)

Use of insulin at baseline (y/n)

Smoking status—current smoker (y/n) eGFR (document what calculation used if this info is available)

Serum creatinine (in case eGFR needs to be calculated)

Urinary albumin creatinine ratio in mg/g

Total/HDL/LDL cholesterol in mmol/l

Systolic blood pressure (mm Hg)

Diastolic blood pressure (mm Hg)

Body weight (kg)

Height (m)

HbA1c (% or mmol/mol)

Body Mass Index (kg/m²)

Body weight and height (kg, m)

Cardiovascular outcome: MACE composite endpoint where available along with individual components (usually cardiovascular death, non-fatal myocardial infarction and non-fatal stroke—but check study documents) and hospitalisation for heart failure where available

Adverse events

Trial identifier

Trial title

Brief description

Phase

Single vs multicentre trial

Geographical location of trial

Study design (eg, blinded)

Sponsor (eg, Industry sponsor)

Date of trial completion

Inclusion/exclusion criteria

Study enrolment number

Intervention drug (generic names)

Comparator drug(s)/regimes

Dosage and frequency of medications

Other drugs allowed in arms

Duration of follow-up for each outcome independently